Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program
MT newswire2026/10/05 11:4307:43 AM EDT, 10/05/2026 (MT Newswires) -- Nurix Therapeutics (NRIX) and Gilead Sciences (GILD) agreed on a two-year research term extension for an undisclosed oncology program under their ongoing strategic collaboration, the second extension for the same program, Nurix said Monday. The company also said it will receive a $10 million extension fee under the amended collaboration deal with Gilead. The collaboration dates back to 2019, and as of May 2026, Nurix is eligible to receive up to about $1.30 billion in additional fees and milestone payments, according to the statement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Crypto prices
More
